|
Investigating the effect of edaravone on the recovery of ischemic stroke patients in Jalil Yasuj Hospital in 2022-03: A double-blind clinical trial study
|
Saeed Razmeh   , Soleiman Afroughi , Sima Shamsi pour , Amir Mohammad Dashti1 |
| 1- , amirmohammaddashty@gmail.com |
|
|
Abstract: (329 Views) |
Background: With the rapid increase of the elderly population and the continuous increase of cardiovascular diseases, the incidence of acute ischemic stroke has increased year by year and brings a significant health burden. On the other hand, due to the complex pathological process, using only one agent in the treatment of ischemia does not seem ideal. Therefore, studies are expanding to find effective compounds and methods. Edaravone is a drug that appears to help in the treatment of this disease due to its antioxidant properties. Therefore, in this study, the effect of Edaravone on the recovery of ischemic stroke patients was investigated.
Methods: In this clinical trial study, 60 patients who were admitted to Shahid Jalil Hospital in Yasuj City in 2022-23 with stroke symptoms in the first 24 hours, 30 people were randomly assigned to the control group and 30 people to the intervention group ( item) were divided. The intervention group received 30 mg of the drug dissolved in 100 mg of normal saline for 60 minutes twice a day for 10 days, and the control group received normal saline infusion as a placebo. Also, both groups received standard stroke treatment and other symptomatic treatment as needed. NIHSS of both groups was measured by a neurologist at the time of hospitalization and at the time of discharge. The findings were analyzed using SPSS version 27 software.
Result: The results of the demographic findings of the study showed that there is no significant difference between the two groups in terms of age, sex, education level, and body mass index (BMI) (p < 0.05). Also, no significant difference was observed during hospitalization (p < 0.05). In examining the disease history and related risk factors, there was no statistically significant relationship between the case group and the control group in terms of complications (p < 0.05). In the examination of the relationship between the NIHSS score before and after the intervention, it was shown that there is a significant difference in the control group and the case so that after the intervention, the NIHSS score decreased significantly, which indicates the positive effect of the drug on this variable. (p > 0.05).
Conclusion: The findings in the present study showed that Edaravone cannot be a potential treatment for acute ischemic stroke patients. However, according to the results of previous studies and the results of the present study, to evaluate the effectiveness of this drug in acute ischemic stroke patients, more investigations should be done so that the use of this drug can be added to the therapeutic strategies used in treatment. |
|
| Keywords: Edaravone, acute ischemic stroke, Hypertension, clinical trial study |
|
|
|
Type of Study: Applicable |
Subject:
Special
Received: 2024/10/7 | Accepted: 2024/12/4 | Published: 2025/05/6
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
